Indegene competitors

John Francis Crowley (born April 7, 1967) is an American biotechnology executive and entrepreneur and the chairman and CEO of Amicus Therapeutics. He co-founded Novazyme Pharmaceuticals with William Canfield, which was later acquired by Genzyme Corporation, and founded Orexigen Therapeutics. In 2006, he was profiled in the book The Cure: How a Father Raised $100 Million – And Bucked the Medical Establishment – In a Quest to Save His Children by Geeta Anand. In 2010, Crowley released his memoir, Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy. Crowley and his family were the inspiration for the movie Extraordinary Measures starring Harrison Ford and Brendan Fraser in 2010.

Jean-Jacques Bienaime is a Board Member at Biotechnology Innovation Organization - BIO, Director at INCYTE CORP, and Chairman/CEO at BioMarin Pharmaceutical Inc and is based in Novato, California. He has experience at Rhône Poulenc Rorer and has worked as President/CEO at GENENCOR INTERNATIONAL INC, Board Member at NeurogesX Inc, and Marketing Director at Genentech. Jean attended ESCP Europe, Ecole Superieure de Commerce de Paris between 1974 and 1976, and University of Pennsylvania.

Michael A. Mussallem, age 56, has been chairman and CEO of Edwards Lifesciences, Inc. since 2000. Prior to 2000, Mussallem held a variety of positions with increasing responsibility in engineering, product development and senior management at Baxter International Inc., including Group Vice President of its CardioVascular business from 1994 to 2000 and Group Vice President of the Biopharmaceutical business from 1998 to 2000. From 1996 until 1998, he was the Chairman of Baxter's Asia Board overseeing Baxter's operations throughout Asia. Mr. Mussallem is chairman of the board of directors of the Advanced Medical Technology Association (AdvaMed), and serves as a member of the board for Advanced Medical Optics. He is also on the boards and executive committees of the California Healthcare Institute and OCTANe, and is a trustee of the University of California, Irvine Foundation. He received a bachelor's degree in chemical engineering in 1974 and an honorary doctorate in 1999 from the Rose-Hulman Institute of Technology in Indiana.

Alexander Hardy is the CEO of Genentech. Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.